Related by context. All words. (Click for frequent words.) 73 discontinuations due 70 TEAEs 68 events SAEs 66 stent thromboses 65 events TEAEs 65 Adverse events 65 oxycodone CR 64 hematologic toxicity 64 treatment emergent adverse 64 dose limiting toxicities 64 ocular adverse 64 ALT flares 64 events AEs 63 AEs 63 Discontinuations 63 thromboembolic events 63 PASI scores 62 cerebrovascular events 62 ARCALYST ® 62 elotuzumab 62 virologic failure 62 QTc prolongation 62 febrile neutropenia 62 placebo dexamethasone 62 laboratory abnormalities 62 definite stent thrombosis 62 FOLPI 61 hematologic adverse 61 hypoglycemic events 61 REYATAZ r arm 61 comparator arm 61 Serious adverse reactions 61 events MACE 61 certolizumab 61 tapentadol ER 61 SAEs 61 Stent thrombosis 61 Serious Adverse Events 61 desvenlafaxine succinate 61 tirofiban 61 lopinavir r arm 61 hematological toxicity 61 APTIVUS r 61 gastrointestinal toxicity 60 AZT zidovudine Retrovir 60 divalproex sodium 60 IIIa inhibitor 60 Treatment emergent adverse 60 diarrhea nausea fatigue 60 arterial thromboembolic events 60 toxicities 60 anemia neutropenia 60 Viread Emtriva 60 thromboembolic 60 tolvaptan 60 OADs 60 Serious AEs 60 NEUPOGEN 60 hematological adverse 60 chlorambucil 60 RLAI 60 mg BID 60 DLTs 60 virologic breakthrough 59 ATACAND 59 valsartan 59 severe hypersensitivity reactions 59 oral olanzapine 59 insulin detemir 59 neutropenia 59 mcg QD 59 extrapyramidal symptoms 59 ABC/3TC 59 nadolol 59 TDF FTC 59 Torsades de Pointes 59 thrombotic events 59 limiting toxicity 59 teriflunomide 59 severe exacerbations 59 binary restenosis 59 receiving ISENTRESS 59 incidence ≥ 59 achieved ACR# 59 PREZISTA r arm 59 FluCAM arm 59 peripheral sensory neuropathy 59 nadroparin 59 NATRECOR R 59 Pred Forte 59 concomitant AEDs 59 hepatotoxicity 59 unfractionated heparin UFH 58 myocardial infarctions 58 #mg/day [001] 58 endoscopic remission 58 prednisone prednisolone 58 Erythropoietic therapies may 58 abacavir 58 mcg albinterferon alfa 2b 58 recurrent ischemia 58 oral diclofenac 58 ARB telmisartan 58 cabazitaxel 58 mg TID 58 mg kg dose 58 gastrointestinal toxicities 58 Discontinuation 58 patients evaluable 58 mg QD 58 neutropenia anemia 58 fluvastatin 58 transaminase elevations 58 Thrombotic events 58 nonfatal MI 58 nasopharyngitis 58 enalapril 58 myopathy rhabdomyolysis 58 Aloxi injection 58 hypersensitivity reactions 58 fondaparinux 58 TAXUS Stent 58 #mg BID [003] 58 simvastatin ezetimibe 58 hypoglycaemic episodes 58 mycophenolate mofetil 58 VIRAMUNE 58 cytogenetic response 58 neutropenia thrombocytopenia 58 bezafibrate 58 receiving INTRON 58 macrovascular events 58 ximelagatran 58 mcg kg REBETOL 58 deep venous thromboses 58 zolmitriptan 58 β blockers 57 intravenous bisphosphonates 57 TYSABRI treated 57 lipid lowering agents 57 reinfarction 57 adjunctive placebo 57 TNF antagonist 57 torsemide ER 57 oral levofloxacin 57 thromboembolism 57 severe hypoglycemic 57 REVLIMID ® 57 remission CR 57 sotalol 57 acarbose 57 Fludara 57 receiving VICTRELIS 57 composite endpoint 57 thrombocytopenia 57 postoperative mortality 57 rFVIIa 57 MoxDuo TM IR 57 mcg BID 57 FOLFIRI 57 Febrile neutropenia 57 haematologic 57 VT VF 57 posaconazole 57 ARCOXIA 57 piperacillin tazobactam 57 flutamide 57 infusion reactions 57 leukopenia 57 diameter stenosis 57 hypomagnesemia 57 paliperidone ER 57 mg/m2 dose 57 angiographic outcomes 57 bivalirudin 57 mitoxantrone 57 dalteparin 57 genotypic resistance 57 oral antidiabetic drugs 57 nicardipine 57 neutropenia dehydration dyspnea 57 LEXIVA r 57 lacosamide 57 rizatriptan 57 active comparator 57 venlafaxine ER 57 headache nasopharyngitis 57 ritonavir boosted atazanavir 57 coadministration 57 CIMZIA TM certolizumab pegol 57 adalimumab 57 tipranavir r 57 myelosuppression 57 QT prolongation 57 eptifibatide 57 systemic absorption 57 Peg IFN 57 mg dose 57 statistically significant differences 57 abciximab 57 CANCIDAS 57 symptomatic VTE 57 HbA 1c levels 57 aspirin clopidogrel 57 elevated ALT 57 concomitant medications 57 ARCALYST 57 venous thromboembolic events 56 recurrent VTE 56 plus methotrexate 56 alpha interferons 56 PRADAXA 56 nonrandomized 56 LPV r 56 evaluable subjects 56 valdecoxib 56 nonhematologic adverse reactions 56 renal toxicity 56 Toxicities 56 statin monotherapy 56 gout flares 56 unfavorable variances 56 nephrotoxicity 56 prolonged QT interval 56 AGILECT R 56 cytopenias 56 headache nausea diarrhea 56 adefovir 56 lopinavir r 56 MYCAMINE 56 achieved statistical significance 56 revascularizations 56 GSK# [001] 56 Infusion Reactions Severe 56 evaluable 56 tamsulosin 56 adalimumab Humira 56 pegylated liposomal doxorubicin 56 EXJADE 56 receiving golimumab 56 Secondary endpoints 56 solifenacin 56 Thalomid ® 56 nonvertebral fractures 56 COPD exacerbations 56 FROVA 56 mg RDEA# 56 enoxaparin 56 QTcF 56 discontinuation 56 perioperative mortality 56 ug dose 56 monotherapy 56 primidone 56 Lamictal XR 56 AGILECT ® 56 abacavir lamivudine 56 telaprevir dosing 56 CYPHER Stent 56 oral vancomycin 56 ACTEMRA TM 56 undetectable HBV DNA 56 irbesartan 56 hypophosphatemia 56 ventricular tachyarrhythmia 56 virologic response 56 mg ustekinumab 56 intracranial hemorrhage ICH 56 salmeterol HFA MDI 56 sternal wound infections 56 glimepiride 56 postintervention 56 ziprasidone 56 beta blocker therapy 56 doxorubicin cyclophosphamide 56 Treatment discontinuations due 56 QT interval prolongation 56 lenalidomide dexamethasone 56 ribavirin therapy 56 leucopenia 56 dapagliflozin plus 56 angiographic restenosis 56 BENICAR HCT 56 PREZISTA r 56 ipsilateral stroke 56 NATRECOR ® 56 Thal Dex 56 decitabine 56 venlafaxine XR 56 XIENCE V demonstrated 56 docetaxel chemotherapy 56 vinorelbine 56 Neulasta ® 56 cardiovascular ischemic 56 revascularization procedures 56 iniparib 56 SVR# 56 tenofovir emtricitabine 56 liver transaminases 56 plus MTX 56 VIIBRYD 56 virological failure 56 gastrointestinal bleeds 56 μg dose 56 Adverse reactions 56 benazepril 56 plus gemcitabine 56 annualized relapse 56 neutrophil counts 56 prespecified 56 hepatic dysfunction 56 LOVENOX R 56 sitagliptin 56 pyrexia mucositis sepsis febrile 56 bovine thrombin 56 hematological toxicities 56 moderate renal impairment 56 avosentan 56 interferon gamma 1b 56 antiandrogen 55 adjunctive ABILIFY 55 infusional 55 chlorthalidone 55 ritonavir boosted lopinavir 55 CIMZIA TM 55 olmesartan 55 non selective NSAIDs 55 GnRH agonists 55 endometrial hyperplasia 55 peginterferon alfa 2b 55 ORENCIA ® 55 mcg Albuferon 55 alanine aminotransferase 55 pooled comparator 55 TELINTRA 55 ALT elevations 55 adverse reactions observed 55 goserelin 55 Vfend 55 target lesion revascularization 55 TMC# r 55 secondary efficacy endpoints 55 Elitek 55 Flu Cy 55 CsA 55 Tekamlo 55 urate lowering 55 abatacept 55 Aptivus ® 55 lumbar spine BMD 55 HMG CoA reductase inhibitors 55 recurrent venous thromboembolism 55 hemorrhagic complications 55 oral allopurinol 55 postoperative chemotherapy 55 nondiabetic patients 55 placebo controlled studies 55 atazanavir ritonavir 55 SSRI SNRI 55 timepoints 55 CIMZIA ™ 55 salmeterol fluticasone 55 Peripheral edema 55 doxorubicin docetaxel 55 rosuvastatin #mg 55 rebleeding 55 nelfinavir 55 antihypertensive drugs 55 dexmedetomidine 55 MACCE 55 rimonabant #mg 55 ancrod 55 clinically meaningful differences 55 ONTAK 55 somnolence dizziness 55 #mg BID [001] 55 MIRAPEX 55 PEG Intron 55 ACEIs 55 LVEF 55 RAPTIVA 55 Alkeran 55 p = NS 55 fosamprenavir 55 constipation nausea 55 XIENCE V PROMUS Stent 55 quetiapine 55 headache diarrhea nausea 55 levetiracetam 55 ACTEMRA 55 Actimmune R 55 HAM D# scores 55 syncope fainting 55 amiodarone 55 androgen suppression 55 lamotrigine 55 Discontinuations due 55 splenectomized patients 55 baseline HbA1c 55 neutropenia febrile neutropenia 55 pegylated interferon alfa 2b 55 levosimendan 55 XOPENEX Inhalation Solution 55 lymphopenia 55 Starlix 55 LHRH agonists 55 refractory gout 55 FDA defined valvulopathy 55 Certolizumab 55 mg BID dose 55 endophthalmitis 55 Desmopressin 55 gemifloxacin 55 thrombocytopenic patients 55 mg doses 55 bosentan 55 EDSS scores 55 diarrhea nausea vomiting 55 ALVESCO 55 postoperative infections 55 dizziness nausea diarrhea 55 EDARBI 55 acute gout flares 55 carboplatin paclitaxel 55 5-FU/LV 55 hyperkalemia 55 Navelbine 55 AGGRASTAT R 55 CCyR 55 receiving prophylactic anticoagulation 55 idraparinux 55 aprepitant 55 Lucentis monotherapy 55 REYATAZ ritonavir 55 gastrointestinal adverse reactions 55 indapamide 55 antiplatelet drugs 55 darunavir r 55 TORISEL 55 receiving XGEVA 55 MEVACOR 55 CAELYX 55 thrombolytic agents 55 dose regimens 55 adverse reactions 55 clinically meaningful improvements 55 montelukast 55 DAPT 55 generalized seizures 55 treatment emergent AEs 55 complete cytogenetic response 54 clopidogrel Plavix 54 Folfox 54 Anaphylactic reactions 54 divalproex 54 tumor regressions 54 LATUDA 54 sirolimus eluting stent 54 certolizumab pegol 54 PEGINTRON TM 54 morphometric vertebral fractures 54 HBeAg seroconversion 54 intracerebral hemorrhage 54 glycoprotein IIb IIIa inhibitor 54 receiving VELCADE 54 sustained virologic response 54 pulmonary toxicity 54 oxcarbazepine 54 gastrointestinal perforation 54 Baseline characteristics 54 FOSRENOL ® 54 HBeAg negative patients 54 bisoprolol 54 nonsignificant 54 mcg doses 54 Free Survival PFS 54 pomalidomide 54 rabeprazole 54 latrepirdine 54 atazanavir 54 renal flares 54 dacarbazine 54 infliximab 54 locoregional recurrence 54 MADRS score 54 venlafaxine Effexor 54 patients receiving ERBITUX 54 vicriviroc 54 danazol 54 #mg QD [002] 54 evaluable patients 54 #mg/m# [001] 54 QTc interval 54 hematologic toxicities 54 TMP SMX 54 olanzapine LAI 54 risperidone Risperdal 54 QTc 54 micafungin 54 conventional antipsychotics 54 Kaplan Meier estimates 54 MCyR 54 lumiracoxib 54 lispro 54 fenofibric acid 54 hypercalcemia 54 estramustine 54 biologic DMARD 54 PENTASA 54 Hypotension 54 linaclotide treated 54 severe neutropenia 54 pegIFN 54 dose cohorts 54 doxazosin 54 INTEGRILIN 54 LEVAQUIN ® 54 ketoconazole 54 fluoxetine paroxetine 54 pravastatin 54 visilizumab 54 paroxetine Paxil 54 moderately emetogenic 54 cobiprostone 54 renal impairment 54 hypotension 54 symptomatic hypotension 54 dose titration 54 mg clopidogrel 54 plus dexamethasone 54 corticosteroid therapy 54 unresectable HCC 54 baseline A1C 54 IRLS score 54 parkinsonian symptoms 54 interferon ribavirin 54 PDE4 inhibitors 54 octreotide 54 nocturnal hypoglycaemia 54 ULORIC 54 Hepatotoxicity 54 REMICADE ® 54 pamidronate 54 lactic acidosis 54 experienced hypomagnesemia 54 timepoint 54 oxymorphone ER 54 1mg dose 54 acromegalic patients 54 oxycodone IR 54 Arixtra 54 zidovudine lamivudine 54 antiretroviral naive 54 prednisone prednisolone plus 54 antiarrhythmic drug 54 omecamtiv mecarbil 54 RITUXAN 54 PEG INTRON 54 Epzicom 54 antithrombotics 54 paclitaxel eluting stents 54 pruritus itching 54 gout flare 54 del 5q MDS 54 Zocor simvastatin 54 CRp 54 prolactin levels 54 Rituxan infusion 54 peginterferon alfa 54 hepatic failure 54 degarelix 54 pioglitazone 54 Hypersensitivity reactions 54 UPDRS motor 54 fatigue asthenia 54 partial remissions 54 delayed CINV 54 hepatic adverse 54 4mg/kg 54 myelosuppressive 54 Eloxatin R 54 COZAAR 54 sitaxsentan 54 ZYVOX 54 achieved CCyR 54 TAXUS Express Stent 54 vandetanib 54 + PH# 54 Dacogen injection 54 GI bleeds 54 lipid lowering drugs 54 Mg Uk 54 cangrelor 54 oral hypoglycemic agents 54 squamous histology 54 periprocedural 54 pyridostigmine 54 underwent CABG 54 beta blockers ACE inhibitors 54 Events MACE 54 glatiramer acetate 54 sirolimus stent 54 ischemic complications 54 IXEMPRA 54 reoperations 54 Seroquel quetiapine fumarate 54 ORENCIA R 54 bolus dose 54 daunorubicin 54 Neutropenia 54 aldosterone antagonist 54 demonstrated clinically meaningful 54 target vessel revascularization 53 palonosetron 53 PLAVIX 53 REMINYL ® 53 parecoxib 53 plus GP IIb 53 neutropaenia 53 Primary endpoints 53 d4T 53 placebo 53 AGGRASTAT ® 53 prazosin 53 octreotide LAR 53 cardiac toxicity 53 blood Phe 53 CRESTOR #mg 53 antiarrhythmic 53 FluCAM 53 intima media thickness 53 R# #mg BID 53 cisplatin gemcitabine 53 plus glycoprotein IIb 53 ropivacaine 53 hypersensitivity allergic reactions 53 PRADAXA #mg 53 antiepileptic drugs 53 isoproterenol 53 pulmonary exacerbations 53 Secondary endpoints include 53 symptomatic atrial fibrillation 53 subcutaneous insulin 53 ventricular tachycardia VT 53 #mg dose [003] 53 valacyclovir 53 dose cytarabine 53 fibrinolytic 53 #.#/#.# mmHg [001] 53 generalized edema 53 pharmacokinetic interactions 53 relapsed MM 53 coronary stenosis 53 FOLFOX4 53 COPEGUS 53 RSD# oral 53 BEACOPP 53 Viread Emtriva Sustiva 53 stent thrombosis 53 canakinumab 53 nasopharyngitis headache 53 angiotensin converting enzyme inhibitor 53 imipramine 53 pericardial effusion 53 metformin monotherapy 53 ddI 53 TRIZIVIR 53 dextromethorphan quinidine 53 peg IFN 53 fluconazole 53 elevated liver enzymes 53 forodesine 53 placebo controlled trials 53 FOLFOX 53 opioid naïve 53 pravastatin Pravachol 53 infliximab Remicade 53 atheroma volume 53 DOXIL 53 Severe hypersensitivity reactions 53 Dermatologic toxicities 53 QTc intervals 53 repeat revascularization 53 LAMICTAL 53 PLAVIX R 53 neuropsychiatric events 53 bone marrow suppression 53 vasogenic edema 53 thrombocytopenic 53 CR nPR 53 BeneFIX 53 terfenadine 53 Serious ocular 53 ACEI ARB 53 HbA1c levels 53 anemia hemoglobin 53 comparator PI r 53 μg doses 53 ARIXTRA 53 arterial thromboembolic 53 THALOMID 53 sirolimus 53 steroid dexamethasone 53 oral antidiabetes 53 PROMACTA 53 metoprolol 53 ramipril 53 serum creatinine levels 53 acute coronary syndromes ACS 53 BYSTOLIC 53 voriconazole 53 clinically meaningful reductions 53 nonvertebral fracture 53 serum phosphate 53 telbivudine 53 cobicistat 53 Dasatinib 53 plus COPEGUS 53 valvulopathy 53 VELCADE melphalan 53 eplerenone 53 melphalan prednisone 53 atorvastatin Lipitor 53 phenytoin 53 Atacand 53 unfractionated heparin 53 experienced virologic failure 53 inflammatory lesions 53 postoperative morbidity 53 randomized #:#:# 53 efalizumab 53 plus OBT 53 antimuscarinic 53 glyburide 53 STRIDE PD 53 serum calcium levels 53 seropositive patients 53 erythropoietic 53 microgram kg 53 INTRON 53 NNRTI resistance 53 Cmax 53 zonisamide SR 53 conjugated equine estrogen 53 candidemia 53 nonfatal stroke 53 VIRAMUNE XR 53 aripiprazole Abilify 53 oral prednisolone 53 tolterodine ER 53 metformin accumulation 53 Thorough QT 53 Crestor rosuvastatin 53 verapamil 53 severe hypoglycemia 53 ibandronate 53 Atrasentan 53 neuropsychiatric symptoms 53 extrapyramidal side 53 Lantus R 53 pruritis 53 COPD exacerbation 53 noncardiac 53 severe asthma exacerbations 53 graft occlusion 53 febuxostat 53 VFEND 53 interferon alfa 2b 53 azathioprine 53 inhaled budesonide 53 nonfatal myocardial infarction MI 53 Liver toxicity 53 candesartan 53 pegylated interferon alpha 53 dexamethasone Decadron 53 interferon beta 1b 53 CYPHER ® 53 intravascular hemolysis 53 LEXIVA 53 baminercept 53 intermittent dosing 53 balsalazide 53 generalized tonic clonic seizures 53 alicaforsen enema 53 apremilast 53 PRAVACHOL R 53 Renal impairment 53 mycophenolate mofetil MMF 53 tiotropium 53 overlapping toxicities 53 DMARDS 53 LMWH 53 serum urate 53 Known hypersensitivity 53 #mg doses [002] 53 analgesic medications 53 hip BMD 53 XELOX 53 ß blockers 53 intracranial bleeding 53 tapentadol IR 53 ischemia driven 53 Engerix B 53 Postoperative complications 53 hepatic enzymes 53 hemorrhagic strokes 53 adrenal insufficiency 53 NPH insulin 53 bicifadine 53 elevated LDH 53 cilostazol 53 AVINZA 53 intraoperative complications 53 alvimopan 53 symptom exacerbation 53 Optivar 53 antiemetics 53 YMRS 53 alfuzosin 52 sargramostim 52 pramipexole 52 retrograde ejaculation 52 thrombotic thromboembolic complications 52 retinal vein occlusion 52 serum phosphate levels 52 paresthesias 52 telmisartan 52 glycated hemoglobin levels 52 Doxil ® 52 ticagrelor 52 JANUVIA 52 interferon alfa 52 prolactin elevation 52 prespecified secondary 52 gadobutrol 52 #mg/day [002] 52 INVEGA ® SUSTENNA ® 52 Rasilez Tekturna 52 mitoxantrone plus 52 fingolimod 52 serum triglycerides 52 timolol 52 torsade de pointes 52 caspofungin 52 neuropsychiatric adverse 52 GP IIb IIIa inhibitor 52 chemoradiotherapy 52 INFERGEN 52 multivariate adjustment 52 angina pectoris 52 NYHA Class II 52 IFN alfa 52 ventricular fibrillation VF 52 intravenous dosing 52 rilonacept 52 lymphocytosis 52 variceal bleeding 52 ezetimibe simvastatin 52 microbiological eradication 52 opioid induced bowel dysfunction 52 resuscitated cardiac arrest 52 receiving SIMPONI 52 azacitidine 52 VaD 52 CVD mortality 52 mg administered orally 52 #mg dose [001] 52 GnRH agonist 52 coxib 52 exemestane 52 nephrotoxic 52 paricalcitol 52 Triapine R 52 QVA# 52 telcagepant 52 hypokalemia 52 Mylotarg 52 icatibant 52 ARIMIDEX 52 paroxetine sertraline 52 PREZISTA ritonavir 52 Pharmacokinetic parameters 52 serologically active patients 52 Benazepril 52 Durezol 52 angioedema 52 Cimzia TM 52 symptomatic intracranial 52 efavirenz EFV 52 amenorrhea 52 clopidogrel 52 anthracycline taxane 52 unstable angina pectoris 52 3TC lamivudine Epivir 52 thienopyridine 52 ticlopidine 52 dose atorvastatin 52 neutropenic fever 52 ocrelizumab 52 Lantus ® 52 SUSTIVA 52 terazosin 52 glipizide 52 anaphylactoid reactions 52 thrombophlebitis 52 elagolix 52 Eraxis 52 nausea constipation 52 hematologic adverse reactions 52 entecavir 52 Hematologic 52 Fibrillex TM 52 pCR 52 advanced adenomas 52 myocardial infarction stroke 52 serum phosphorous 52 clodronate 52 peginterferon 52 LT NS# 52 metformin sulfonylurea 52 zoledronate 52 romiplostim 52 postoperative complication 52 ethambutol 52 corticosteroid dose 52 raltegravir 52 omeprazole Prilosec 52 rHuEPO 52 SPRYCEL ® 52 acneform rash 52 pegfilgrastim 52 DAS# scores 52 HbA1C levels 52 plasma uric acid 52 atherothrombotic events 52 highly emetogenic 52 bone marrow reticulin 52 8mg/kg 52 HAM D# 52 symptomatic hypoglycemia 52 adverse cytogenetics 52 MULTAQ 52 Angioedema 52 tolerability profiles 52 Hepsera 52 headache abdominal pain 52 ID TLR 52 JANUMET 52 non valvular atrial 52 telithromycin 52 postoperative bleeding 52 trospium 52 aspirin heparin 52 hallucinations dyskinesia 52 IOP lowering 52 q#h 52 adriamycin 52 colorectal adenoma 52 atypical antipsychotic drugs 52 rosuvastatin Crestor 52 cardiac repolarization 52 tamoxifen Nolvadex ® 52 mcg kg 52 noncardiovascular mortality 52 nodular partial response 52 COREG 52 quetiapine XR 52 serious Interstitial Lung 52 microvascular complications 52 recurrent glioblastoma multiforme 52 cytogenetic abnormalities 52 MIs 52 Targretin capsules 52 ezetimibe 52 CR CRu 52 nonresponders 52 Viread Emtriva SUSTIVA 52 EFFEXOR XR 52 lamivudine 52 AVONEX ® 52 boosted protease inhibitor 52 allopurinol 52 Cleviprex TM clevidipine 52 NATRECOR 52 MARINOL R 52 abacavir Ziagen 52 mucocutaneous reactions 52 secondary efficacy endpoint 52 otamixaban 52 Paxil paroxetine 52 prospectively stratified 52 beclomethasone dipropionate 52 RISPERDAL ® 52 anakinra 52 olanzapine Zyprexa 52 chemotherapy induced neutropenia 52 dutasteride 52 amprenavir 52 patients undergoing CABG